Una Ryan - Albany Molecular Insider

AMRI -- USA Stock  

null 21.74  0.00  0.00%

Lead Independent Director
Dr. Una S. Ryan Ph.D., OBE, is the Lead Independent Director of Albany Molecular Research Inc., since October 2006. She is currently President of Diagnostics for All, a nonprofit focused on lowcost and easytouse diagnostics for the developing world. Previously, she was President and CEO of Waltham Technologies, Inc. a company in the Clean WaterClean Energy business. Concurrently, she holds the position of research professor of medicine at Boston University School of Medicine. Prior to joining Waltham, she was President and CEO of AVANT Immunotherapeutics, Inc. and also a member of its Board of Directors, 1993 to 2007. Prior to AVANT, she was director of Health Sciences at Monsanto Company, 1990 to 1993. Before that, she held a number of positions in academia, including research professor of surgery at Washington University School of Medicine in St. Louis, 1990 to 1994 and professor of medicine at the University of Miami School of Medicine, 1972 to 1989. Dr. Ryan graduated from Englands Bristol University, with B.Sc. degrees in Zoology, Chemistry, and Microbiology. In 2009 she received an Honorary D.Sc. from Bristol University. She received a Ph.D. from Cambridge University. Dr. Ryan has served on several private company boards and industry trade organizations, including the board of BIO, and is past chair of the Massachusetts Biotechnology Council. In 2002, she was awarded the Order of the British Empire for her work to foster and promote biotechnology.
Age: 72  Director Since 2010      
518 512-2000  www.amriglobal.com

Management Efficiency

The company has return on total asset (ROA) of 0.36 % which means that it generated profit of $0.36 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (20.61) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 647.96 M in liabilities with Debt to Equity (D/E) ratio of 204.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Albany Molecular Research has Current Ratio of 0.67 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

John DineenCognizant Technology Solutions
2017
Sandra WijnbergAutomatic Data Processing
2016
Stephen ChazenEcolab
2013
Stephan JamesFidelity National Information S
2009
Betsy AtkinsCognizant Technology Solutions
2017
Thomas HagertyFidelity National Information S
2006
Joel JohnsonEcolab
1996
Suzanne VautrinotEcolab
2015
Leslie MumaFidelity National Information S
2013
Charles NoskiBooking Holdings
2015
Ellen AlemanyFidelity National Information S
2014
Jerry LevinEcolab
N/A
Richard MasseyFidelity National Information S
2009
Michael GregoireAutomatic Data Processing
2014
Jeffrey LehmanInfosys Limited
2006
Thomas WendelCognizant Technology Solutions
2001
David MacLennanEcolab
2015
Jan DocterBooking Holdings
2007
Nancy PeretsmanBooking Holdings
1999
Michael LarsonEcolab
2012
Ellen AlemanyAutomatic Data Processing
2011

Entity Summary

Albany Molecular Research, Inc., a contract research and manufacturing company, offer integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. Albany Molecular Research (AMRI) is traded on NASDAQ in USA. It is located in 26 Corporate Circle, Albany, NY 12203, United States and employs 2,220 people.

Albany Molecular Res Leadership Team

George Svokos, COO, MBA
Arthur Roth, Director
Gerardo Gutierrez, Director
Thomas Ambra, Chairman, Ph.D
Lori Henderson, President
Milton Boyer, President
Anthony Maddaluna, Director, MBA
Kenneth Hagen, Director, CPA
Fernando Napolitano, Director
Una Ryan, Director
David Deming, Director
Kevin Connor, Director
Jimmy Wang, Executive, Ph.D
Gabriel Leung, Director
Steven Hagen, SVP
Christopher Conway, President
Felicia Ladin, President
Veronica Jordan, Director, Ph.D
William Marth, CEO, MBA

Stock Performance Indicators

Did you try this?

Run My Watchlist Analysis Now
   

My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
All  Next Launch My Watchlist Analysis

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Albany Molecular and SAP SE. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.